$AVRW
Avenir Wellness Solutions, Inc.

2024 Q4 Form 10-Q Financial Statement

#000147793224007414 Filed on November 19, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $192.0K
YoY Change -81.08%
Cost Of Revenue $35.00K
YoY Change -87.41%
Gross Profit $157.0K
YoY Change -78.7%
Gross Profit Margin 81.77%
Selling, General & Admin $660.0K
YoY Change -71.19%
% of Gross Profit 420.38%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $1.000K
YoY Change 0.0%
% of Gross Profit 0.64%
Operating Expenses $660.0K
YoY Change -71.42%
Operating Profit -$503.0K
YoY Change -68.0%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$38.00K
YoY Change -94.17%
Pretax Income -$541.0K
YoY Change -75.67%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$541.0K
YoY Change -75.67%
Net Earnings / Revenue -281.77%
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 78.93M shares 77.99M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $11.00K
Short-Term Investments
Other Short-Term Assets $15.00K
YoY Change -72.73%
Inventory $142.0K
Prepaid Expenses $8.000K
Receivables $33.00K
Other Receivables
Total Short-Term Assets $238.0K
YoY Change -87.96%
LONG-TERM ASSETS
Property, Plant & Equipment $3.000K
YoY Change 50.0%
Goodwill
YoY Change
Intangibles $212.0K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $510.0K
YoY Change -39.64%
TOTAL ASSETS
Total Short-Term Assets $238.0K
Total Long-Term Assets $510.0K
Total Assets $748.0K
YoY Change -73.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.452M
YoY Change 56.08%
Accrued Expenses $1.587M
YoY Change -6.15%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.30M
YoY Change 3.96%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $13.30M
Total Long-Term Liabilities
Total Liabilities $13.30M
YoY Change 3.96%
SHAREHOLDERS EQUITY
Retained Earnings -$126.1M
YoY Change 2.23%
Common Stock $78.00K
YoY Change 6.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$12.55M
YoY Change
Total Liabilities & Shareholders Equity $748.0K
YoY Change -73.48%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$541.0K
YoY Change -75.67%
Depreciation, Depletion And Amortization $1.000K
YoY Change 0.0%
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
33000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
142000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
238000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 usd
CY2024Q3 us-gaap Investments
Investments
264000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
52000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
286000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2452000 usd
CY2024Q3 us-gaap Loans Payable Current
LoansPayableCurrent
0 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12493000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
12493000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1956000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4000 usd
CY2023Q4 us-gaap Investments
Investments
264000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
227000 usd
CY2023Q4 us-gaap Assets
Assets
2607000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
199000 usd
CY2024Q3 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
0 usd
CY2023Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
975000 usd
CY2024Q3 avrw Due From Related Party Current
DueFromRelatedPartyCurrent
0 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
212000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
31000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2452000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1587000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1342000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
45000 usd
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
139000 usd
CY2024Q3 avrw Notes Payables Related Parties Current
NotesPayablesRelatedPartiesCurrent
41000 usd
CY2023Q4 avrw Notes Payables Related Parties Current
NotesPayablesRelatedPartiesCurrent
0 usd
CY2024Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
8713000 usd
CY2023Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
8099000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
13296000 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77993348 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
79000 usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
78000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
113435000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-126132000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-123399000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-12548000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-9886000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
748000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2607000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
56000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
51000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
50000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
81000 usd
us-gaap Inventory Write Down
InventoryWriteDown
-12000 usd
us-gaap Inventory Write Down
InventoryWriteDown
-84000 usd
avrw Fair Value Of Vested Stock Options And Restricted Stock
FairValueOfVestedStockOptionsAndRestrictedStock
71000 usd
avrw Fair Value Of Vested Stock Options And Restricted Stock
FairValueOfVestedStockOptionsAndRestrictedStock
514000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
410000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
87000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
69000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
9000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
270000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
312000 usd
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-4000 usd
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
124000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
0 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
506000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
245000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
106000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-45000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-92000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-20000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
65000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1021000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3319000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
51000 usd
avrw Repayment Of Note Receivable
RepaymentOfNoteReceivable
975000 usd
avrw Repayment Of Note Receivable
RepaymentOfNoteReceivable
750000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
974000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
699000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
45000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
4000 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
139000 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
134000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2754000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2943000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
189000 usd
us-gaap Interest Paid Net
InterestPaidNet
19000 usd
us-gaap Interest Paid Net
InterestPaidNet
9000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Certain reclassifications have been made to prior year’s consolidated financial statements to enhance comparability with the current year’s consolidated financial statements. These reclassifications had no effect on the previously reported net loss.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements, and other factors that management believes to be reasonable. In addition, the Company has considered the potential impact of certain macroeconomic factors, including inflation, rising interest rates, and recessionary pressures, on its business and operations. Although the full impact of these factors is unknown and cannot be estimated reasonably, the Company believes it has made appropriate accounting estimates and assumptions based on the facts and circumstances available as of the reporting date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Significant areas requiring the use of management estimates include, but are not limited to, revenue recognition, the allowance for doubtful accounts, valuation of intangible assets and goodwill, depreciation and amortization useful lives, assumptions used to calculate the fair value of the contingent stock consideration, stock-based compensation, deferred taxes and the assumptions used to calculate fair values of the purchase price allocations and convertible promissory notes. Actual results could differ materially from such estimates under different assumptions or circumstances.</p>
avrw Contingent Stock Consideration Disclosure Textblock
ContingentStockConsiderationDisclosureTextblock
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 17 – CONTINGENT STOCK CONSIDERATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In October 2020, the Company acquired all of the issued and outstanding stock of Sera Labs in exchange for consideration of (i) $1.0 million in cash and (ii) 5,014,868 shares of the Company’s common stock. In addition, the Sera Labs security holders were also entitled to receive up to an additional 5,988,024 shares of the Company’s common stock (the “Clawback Shares”) based on the achievement of certain sales and gross margin milestones through December 31, 2023. As of December 31, 2023, 4,790,419 of the Clawback Shares were earned and the remaining 1,197,605 shares were forfeited and cancelled.</p>
dei Entity Central Index Key
EntityCentralIndexKey
0001643301
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
78925168 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
78925168 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77993348 shares
avrw Warrants Shares
WarrantsShares
0 shares
us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
0 shares
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
0 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-55908
dei Entity Registrant Name
EntityRegistrantName
AVENIR WELLNESS SOLUTIONS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
90-1504639
dei Entity Address Address Line1
EntityAddressAddressLine1
15233 Ventura Blvd
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 420
dei Entity Address City Or Town
EntityAddressCityOrTown
Sherman Oaks
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91403
dei City Area Code
CityAreaCode
424
dei Local Phone Number
LocalPhoneNumber
273-8675
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
443000 usd
CY2023Q4 avrw Due From Related Party Current
DueFromRelatedPartyCurrent
4000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
50000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
70000 usd
CY2024Q3 us-gaap Other Assets
OtherAssets
0 usd
CY2023Q4 us-gaap Other Assets
OtherAssets
36000 usd
CY2024Q3 us-gaap Assets
Assets
748000 usd
CY2024Q3 us-gaap Notes Payable
NotesPayable
107000 usd
CY2023Q4 us-gaap Notes Payable
NotesPayable
0 usd
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
396000 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
416000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
13296000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
78925168 shares
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
113505000 usd
CY2024Q3 avrw Rvenue From Product Sales Net Of Discounts And Refunds
RvenueFromProductSalesNetOfDiscountsAndRefunds
192000 usd
CY2023Q3 avrw Rvenue From Product Sales Net Of Discounts And Refunds
RvenueFromProductSalesNetOfDiscountsAndRefunds
1011000 usd
avrw Rvenue From Product Sales Net Of Discounts And Refunds
RvenueFromProductSalesNetOfDiscountsAndRefunds
919000 usd
avrw Rvenue From Product Sales Net Of Discounts And Refunds
RvenueFromProductSalesNetOfDiscountsAndRefunds
3221000 usd
CY2024Q3 us-gaap Revenues
Revenues
192000 usd
CY2023Q3 us-gaap Revenues
Revenues
1011000 usd
us-gaap Revenues
Revenues
919000 usd
us-gaap Revenues
Revenues
3221000 usd
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
35000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
278000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
187000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
817000 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
157000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
733000 usd
us-gaap Gross Profit
GrossProfit
732000 usd
us-gaap Gross Profit
GrossProfit
2404000 usd
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
660000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2287000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2821000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7446000 usd
CY2024Q3 avrw Change In Fair Value Of Contingent Stock Consideration
ChangeInFairValueOfContingentStockConsideration
0 usd
CY2023Q3 avrw Change In Fair Value Of Contingent Stock Consideration
ChangeInFairValueOfContingentStockConsideration
18000 usd
avrw Change In Fair Value Of Contingent Stock Consideration
ChangeInFairValueOfContingentStockConsideration
0 usd
avrw Change In Fair Value Of Contingent Stock Consideration
ChangeInFairValueOfContingentStockConsideration
-290000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
660000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2305000 usd
us-gaap Operating Expenses
OperatingExpenses
2821000 usd
us-gaap Operating Expenses
OperatingExpenses
7156000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-503000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1572000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2089000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4752000 usd
CY2024Q3 us-gaap Interest Income Operating
InterestIncomeOperating
0 usd
CY2023Q3 us-gaap Interest Income Operating
InterestIncomeOperating
11000 usd
us-gaap Interest Income Operating
InterestIncomeOperating
5000 usd
us-gaap Interest Income Operating
InterestIncomeOperating
43000 usd
CY2024Q3 avrw Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
-19000 usd
CY2023Q3 avrw Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
-648000 usd
avrw Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
-614000 usd
avrw Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
1331000 usd
CY2024Q3 us-gaap Interest Expense Other
InterestExpenseOther
19000 usd
CY2023Q3 us-gaap Interest Expense Other
InterestExpenseOther
15000 usd
us-gaap Interest Expense Other
InterestExpenseOther
32000 usd
us-gaap Interest Expense Other
InterestExpenseOther
42000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-38000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-652000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-641000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1332000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-541000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2224000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2730000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3420000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-541000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2224000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2733000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3420000 usd
CY2024Q3 avrw Earnings Per Shares Basic And Diluted
EarningsPerSharesBasicAndDiluted
-0.01
CY2023Q3 avrw Earnings Per Shares Basic And Diluted
EarningsPerSharesBasicAndDiluted
-0.03
avrw Earnings Per Shares Basic And Diluted
EarningsPerSharesBasicAndDiluted
-0.03
avrw Earnings Per Shares Basic And Diluted
EarningsPerSharesBasicAndDiluted
-0.05
CY2024Q3 avrw Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
78439001 shares
CY2023Q3 avrw Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
72231926 shares
avrw Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
78142983 shares
avrw Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
71717926 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-9886000 usd
CY2024Q1 avrw Fair Value Of Stock Options Granted
FairValueOfStockOptionsGranted
5000 usd
CY2024Q1 avrw Fair Value Of Restricted Stock Units Granted
FairValueOfRestrictedStockUnitsGranted
30000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1295000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-11146000 usd
CY2024Q2 avrw Fair Value Of Stock Options Granted
FairValueOfStockOptionsGranted
5000 usd
CY2024Q2 avrw Fair Value Of Restricted Stock Units Granted
FairValueOfRestrictedStockUnitsGranted
24000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-897000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-12014000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
0 usd
CY2024Q3 avrw Fair Value Of Stock Options Granted
FairValueOfStockOptionsGranted
4000 usd
CY2024Q3 avrw Fair Value Of Restricted Stock Units Granted
FairValueOfRestrictedStockUnitsGranted
3000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-541000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-12548000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-7105000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
2000 usd
CY2023Q1 avrw Fair Value Of Stock Options Granted
FairValueOfStockOptionsGranted
96000 usd
CY2023Q1 avrw Fair Value Of Restricted Stock Units Granted
FairValueOfRestrictedStockUnitsGranted
113000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-209000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-7103000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
32000 usd
CY2023Q2 avrw Fair Value Of Stock Options Granted
FairValueOfStockOptionsGranted
75000 usd
CY2023Q2 avrw Fair Value Of Restricted Stock Units Granted
FairValueOfRestrictedStockUnitsGranted
115000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-987000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-7868000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
9000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
0 usd
CY2023Q3 avrw Fair Value Of Stock Options Granted
FairValueOfStockOptionsGranted
72000 usd
CY2023Q3 avrw Fair Value Of Restricted Stock Units Granted
FairValueOfRestrictedStockUnitsGranted
43000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2224000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-9968000 usd
us-gaap Profit Loss
ProfitLoss
-2733000 usd
us-gaap Profit Loss
ProfitLoss
-3420000 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
43000 usd
avrw Change In Fair Value Of Contingent Stock Consideration
ChangeInFairValueOfContingentStockConsideration
0 usd
avrw Change In Fair Value Of Contingent Stock Consideration
ChangeInFairValueOfContingentStockConsideration
-290000 usd
avrw Fair Value Of Convertible Promissory Notes Adjustment Amount
FairValueOfConvertiblePromissoryNotesAdjustmentAmount
-614000 usd
avrw Fair Value Of Convertible Promissory Notes Adjustment Amount
FairValueOfConvertiblePromissoryNotesAdjustmentAmount
1331000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
122000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
15000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-134000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-38000 usd
CY2024Q3 us-gaap Cash
Cash
11000 usd
CY2024Q3 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
-126100000 usd
CY2024Q3 avrw Working Capital Deficit
WorkingCapitalDeficit
-13100000 usd
CY2024Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
396000 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
416000 usd
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
416000 usd
avrw Additions To Contract Liabilities
AdditionsToContractLiabilities
37000 usd
avrw Contract Liabilities Customer Deposits Returned
ContractLiabilitiesCustomerDepositsReturned
0 usd
avrw Contract Liabilities Transfers To Revenue
ContractLiabilitiesTransfersToRevenue
-57000 usd
CY2024Q3 us-gaap Deferred Revenue
DeferredRevenue
396000 usd
CY2024Q3 us-gaap Advertising Expense
AdvertisingExpense
82000 usd
CY2023Q3 us-gaap Advertising Expense
AdvertisingExpense
802000 usd
us-gaap Advertising Expense
AdvertisingExpense
511000 usd
us-gaap Advertising Expense
AdvertisingExpense
2200000 usd
CY2024Q3 avrw Valuation Allowance Percentage
ValuationAllowancePercentage
1 pure
CY2024Q3 avrw Fair Value Of Series A Note
FairValueOfSeriesANote
4918000 usd
CY2024Q3 avrw Fair Value Of Series B Note
FairValueOfSeriesBNote
3795000 usd
CY2023Q4 avrw Fair Value Of Series A Note
FairValueOfSeriesANote
4597000 usd
CY2023Q4 avrw Fair Value Of Series B Note
FairValueOfSeriesBNote
3502000 usd
avrw Notespayablefairvaluedisclosurebeginning Balance
NotespayablefairvaluedisclosurebeginningBalance
8099000 usd
avrw Changes In Fair Value Of Series A Note
ChangesInFairValueOfSeriesANote
321000 usd
avrw Change In Fair Value Of Series B Notes
ChangeInFairValueOfSeriesBNotes
293000 usd
avrw Notes Payable Fair Value Disclosure Ending Balance
NotesPayableFairValueDisclosureEndingBalance
8713000 usd
avrw Stock Price
StockPrice
0.0519
CY2023 avrw Stock Price
StockPrice
0.0744
avrw Conversion Price
ConversionPrice
1.32
CY2023 avrw Conversion Price
ConversionPrice
1.32
avrw Interest Rate
InterestRate
0.180 pure
CY2023 avrw Interest Rate
InterestRate
0.180 pure
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-541000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2224000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2733000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3420000 usd
CY2024Q3 avrw Weighted Average Common Shares Outstanding Basic And Diluted Shares
WeightedAverageCommonSharesOutstandingBasicAndDilutedShares
78439001 shares
CY2023Q3 avrw Weighted Average Common Shares Outstanding Basic And Diluted Shares
WeightedAverageCommonSharesOutstandingBasicAndDilutedShares
72231926 shares
avrw Weighted Average Common Shares Outstanding Basic And Diluted Shares
WeightedAverageCommonSharesOutstandingBasicAndDilutedShares
78142983 shares
avrw Weighted Average Common Shares Outstanding Basic And Diluted Shares
WeightedAverageCommonSharesOutstandingBasicAndDilutedShares
71717926 shares
CY2024Q3 avrw Basic And Diluted Loss Per Shares
BasicAndDilutedLossPerShares
-0.01
CY2023Q3 avrw Basic And Diluted Loss Per Shares
BasicAndDilutedLossPerShares
-0.03
avrw Basic And Diluted Loss Per Shares
BasicAndDilutedLossPerShares
-0.03
avrw Basic And Diluted Loss Per Shares
BasicAndDilutedLossPerShares
-0.05
avrw Vested Stock Options From The Companys Equity Incentive Plan
VestedStockOptionsFromTheCompanysEquityIncentivePlan
1261182 shares
avrw Vested Stock Options From The Companys Equity Incentive Plan
VestedStockOptionsFromTheCompanysEquityIncentivePlan
1373946 shares
avrw Warrants Shares
WarrantsShares
312500 shares
us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
618327 shares
avrw Anti Dilutive Shares
AntiDilutiveShares
1261182 shares
avrw Anti Dilutive Shares
AntiDilutiveShares
2304773 shares
CY2024Q3 avrw Customer Billed Accounts Receivable
CustomerBilledAccountsReceivable
33000 usd
CY2023Q4 avrw Customer Billed Accounts Receivable
CustomerBilledAccountsReceivable
443000 usd
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2024Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
33000 usd
CY2023Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
443000 usd
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
29000 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
184000 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
8000 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
33000 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
15000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
69000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
52000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
286000 usd
CY2024Q3 avrw Inventory Packaging Components
InventoryPackagingComponents
55000 usd
CY2023Q4 avrw Inventory Packaging Components
InventoryPackagingComponents
84000 usd
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
352000 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
408000 usd
CY2024Q3 us-gaap Inventory Gross
InventoryGross
407000 usd
CY2023Q4 us-gaap Inventory Gross
InventoryGross
492000 usd
CY2024Q3 us-gaap Inventory Adjustments
InventoryAdjustments
-265000 usd
CY2023Q4 us-gaap Inventory Adjustments
InventoryAdjustments
-293000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
142000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
199000 usd
CY2024Q3 us-gaap Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
0 usd
CY2023Q3 us-gaap Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
43000 usd
us-gaap Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
0 usd
us-gaap Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
78000 usd
CY2024Q3 us-gaap Sale Leaseback Transaction Accumulated Depreciation
SaleLeasebackTransactionAccumulatedDepreciation
7000 usd
CY2023Q4 us-gaap Sale Leaseback Transaction Accumulated Depreciation
SaleLeasebackTransactionAccumulatedDepreciation
6000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4000 usd
CY2024Q3 us-gaap Depreciation
Depreciation
1000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
1000 usd
us-gaap Depreciation
Depreciation
1000 usd
us-gaap Depreciation
Depreciation
1000 usd
CY2022Q3 avrw Other Receivables D3
OtherReceivablesD3
1000000.0 usd
CY2024Q3 avrw Less Current Portion Of Notes Receivable
LessCurrentPortionOfNotesReceivable
0 usd
CY2023Q4 avrw Less Current Portion Of Notes Receivable
LessCurrentPortionOfNotesReceivable
-975000 usd
CY2024Q3 avrw Notes Receivable Non Current
NotesReceivableNonCurrent
0 usd
CY2023Q4 avrw Notes Receivable Non Current
NotesReceivableNonCurrent
0 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
458000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
457000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
215000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
160000 usd
CY2024Q3 us-gaap Other Indefinite Lived Intangible Assets
OtherIndefiniteLivedIntangibleAssets
243000 usd
CY2023Q4 us-gaap Other Indefinite Lived Intangible Assets
OtherIndefiniteLivedIntangibleAssets
297000 usd
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
18000 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
20000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
54000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
49000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
15000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
34000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
19000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
17000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
17000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
17000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
124000 usd
CY2024Q3 us-gaap Other Indefinite Lived Intangible Assets
OtherIndefiniteLivedIntangibleAssets
243000 usd
CY2024Q3 avrw Investment In Biopharmaceutical Research Company
InvestmentInBiopharmaceuticalResearchCompany
213000 usd
CY2023Q4 avrw Investment In Biopharmaceutical Research Company
InvestmentInBiopharmaceuticalResearchCompany
213000 usd
CY2024Q3 us-gaap Investments
Investments
264000 usd
CY2023Q4 us-gaap Investments
Investments
264000 usd
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
568000 usd
CY2024Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
568000 usd
CY2024Q3 us-gaap Customer Refund Liability Current
CustomerRefundLiabilityCurrent
584000 usd
CY2023Q4 us-gaap Customer Refund Liability Current
CustomerRefundLiabilityCurrent
566000 usd
CY2024Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
3000 usd
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
0 usd
CY2024Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
352000 usd
CY2023Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
205000 usd
CY2024Q3 us-gaap Accrued Vacation Current And Noncurrent
AccruedVacationCurrentAndNoncurrent
89000 usd
CY2023Q4 us-gaap Accrued Vacation Current And Noncurrent
AccruedVacationCurrentAndNoncurrent
81000 usd
CY2024Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
241000 usd
CY2023Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
154000 usd
CY2024Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
318000 usd
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
336000 usd
CY2024Q3 avrw Accrued Expenses Current Net
AccruedExpensesCurrentNet
1587000 usd
CY2023Q4 avrw Accrued Expenses Current Net
AccruedExpensesCurrentNet
1342000 usd
CY2024Q3 us-gaap Interest Payable Current
InterestPayableCurrent
44000 usd
CY2024Q3 avrw Accrued Interestrelatedpartiescurrent
AccruedInterestrelatedpartiescurrent
3000 usd
CY2023Q4 avrw Accrued Interestrelatedpartiescurrent
AccruedInterestrelatedpartiescurrent
0 usd
CY2024Q3 avrw Interest Expenses For Related Parties
InterestExpensesForRelatedParties
1000 usd
CY2023Q3 avrw Interest Expenses For Related Parties
InterestExpensesForRelatedParties
0 usd
avrw Interest Expenses For Related Parties
InterestExpensesForRelatedParties
3000 usd
avrw Interest Expenses For Related Parties
InterestExpensesForRelatedParties
0 usd
CY2024Q3 us-gaap Other Loans Payable Current
OtherLoansPayableCurrent
0 usd
CY2023Q4 us-gaap Other Loans Payable Current
OtherLoansPayableCurrent
-139000 usd
CY2024Q3 avrw Loan Payable Less Current Portion
LoanPayableLessCurrentPortion
0 usd
CY2023Q4 avrw Loan Payable Less Current Portion
LoanPayableLessCurrentPortion
0 usd
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
-107000 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 usd
CY2024Q3 avrw Note Payable Less Current Portion
NotePayableLessCurrentPortion
0 usd
CY2023Q4 avrw Note Payable Less Current Portion
NotePayableLessCurrentPortion
0 usd
CY2024Q2 avrw Additional Notes Tranches Amount
AdditionalNotesTranchesAmount
350000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
6000 usd
CY2024Q2 avrw One Time Note Interest Charge Percentage Rate
OneTimeNoteInterestChargePercentageRate
0.22 pure
CY2024Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.001
CY2024Q2 avrw Lowest Trading Price Percentage Rate
LowestTradingPricePercentageRate
0.70 pure
CY2024Q3 us-gaap Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
4918000 usd
CY2023Q4 us-gaap Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
4597000 usd
CY2024Q3 us-gaap Convertible Subordinated Debt
ConvertibleSubordinatedDebt
3795000 usd
CY2023Q4 us-gaap Convertible Subordinated Debt
ConvertibleSubordinatedDebt
3502000 usd
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
8713000 usd
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
8099000 usd
CY2024Q3 avrw Less Current Portion Of Convertible Promissory Notes At Fair Value
LessCurrentPortionOfConvertiblePromissoryNotesAtFairValue
8713000 usd
CY2023Q4 avrw Less Current Portion Of Convertible Promissory Notes At Fair Value
LessCurrentPortionOfConvertiblePromissoryNotesAtFairValue
8099000 usd
CY2024Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
0 usd
CY2023Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
0 usd
us-gaap Debt Conversion Converted Instrument Rate
DebtConversionConvertedInstrumentRate
0.18 pure
CY2024Q3 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
1.32
us-gaap Debt Conversion Description
DebtConversionDescription
The Investor will not have the right to convert any portion of the Convertible Notes, to the extent that, after giving effect to such conversion, the Investor (and other certain related parties) would beneficially own in excess of 4.99% of the shares of Common Stock outstanding immediately after giving effect to such conversion. This limit may, from time to time, be increased, up to 9.99%, or decreased
us-gaap Proceeds From Issuance Of Medium Term Notes
ProceedsFromIssuanceOfMediumTermNotes
10000000.0 usd
avrw Warrant Exercisable Shares
WarrantExercisableShares
4145212 shares
avrw Remaining Balance Of Investor Note
RemainingBalanceOfInvestorNote
9900000 usd
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1518194 shares
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
0 usd
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
73000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
243000 usd
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
33000 usd
avrw Weighted Average Remaining Contractual Life Year
WeightedAverageRemainingContractualLifeYear
P0Y11M8D
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
1000000.0 usd
CY2023Q4 avrw Shares Of Common Stock Earned
SharesOfCommonStockEarned
4790419 shares
CY2023Q4 avrw Remaining Shares Forfeited And Cancelled
RemainingSharesForfeitedAndCancelled
1197605 shares
avrw Description Of Lease Agreement
DescriptionOfLeaseAgreement
a lease agreement (the “Lease”), which was originally set to expire on April 30, 2026. Effective on September 6, 2024, the Company early terminated the lease without penalty by mutual agreement with the landlord and the Company vacated the premises. The lease provided for the payment of base monthly rent in the amount of $7 thousand during the first 12 months of the term with an increase of 3% over the base monthly rent beginning on the one-year anniversary of the Lease. The Company previously occupied Suite 801 in the same building under a lease agreement that expired on April 30, 2024
avrw Weighted Average Discount Rate In Percentage
WeightedAverageDiscountRateInPercentage
0.1416 pure
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
50000 usd
CY2024Q3 avrw Right Of Use Lease Liabilities Current
RightOfUseLeaseLiabilitiesCurrent
0 usd
CY2023Q4 avrw Right Of Use Lease Liabilities Current
RightOfUseLeaseLiabilitiesCurrent
45000 usd
CY2024Q3 avrw Right Of Use Lease Liability Noncurrent
RightOfUseLeaseLiabilityNoncurrent
0 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
0 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
45000 usd
CY2023 avrw Weighted Average Remaining Lease Term Operating Lease
WeightedAverageRemainingLeaseTermOperatingLease
P0Y3M14D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1130 pure

Files In Submission

Name View Source Status
0001477932-24-007414-index-headers.html Edgar Link pending
0001477932-24-007414-index.html Edgar Link pending
0001477932-24-007414.txt Edgar Link pending
0001477932-24-007414-xbrl.zip Edgar Link pending
avrw-20240930.xsd Edgar Link pending
avrw_10q.htm Edgar Link pending
avrw_ex311.htm Edgar Link pending
avrw_ex312.htm Edgar Link pending
avrw_ex321.htm Edgar Link pending
avrw_ex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
avrw-20240930_def.xml Edgar Link unprocessable
avrw-20240930_lab.xml Edgar Link unprocessable
avrw-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
avrw_10q_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
avrw-20240930_cal.xml Edgar Link unprocessable